Metabolic side effects and cardiovascular events of diuretics: Should a diuretic remain the first choice therapy in hypertension treatment? The case of yes

Clinical and Experimental Hypertension

Volumn 29, Issue 8, 2007, Pages 503-516

  Papadopoulos, Dimitris P ^a   Papademetriou, Vasilios ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Arrythmias; Cardiovascular events; Diuretics; Hypercholesterolemia; Hypertension; Metabolic side effects; New onset diabetes

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LISINOPRIL; URIC ACID; VERAPAMIL;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ELECTROLYTE BALANCE; ESSENTIAL HYPERTENSION; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPOKALEMIA; META ANALYSIS; METABOLIC DISORDER; MORBIDITY; MORTALITY; NEUROPROTECTION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CHOLESTEROL; DIABETES MELLITUS; DIURETICS; FEMALE; HUMANS; HYPERTENSION; HYPOKALEMIA; MALE; POTASSIUM;

EID: 36849014778     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960701743964     Document Type: Review

References (88)

1. Puschett JB. Diuretics and the therapy of hypertension. Am J Med Sci. 2000 Jan;319(1):1-9.
2. Black HR. The evolution of low-dose diuretic therapy: The lessons from clinical trials. Am J Med. 1996 Sep 30;101(3A):47S-52S
3. Freis ED, Wanko A, Wilson IM, Parrish AE. Chlorothiazide in hypertensive and normotensive patients. Ann N Y Acad Sci. 1958;71(4):450-455.
4. Papademetriou V. Diuretics in hypertension: Clinical experiences. Eur Heart J. 1992;Suppl.G:92-95.
5. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967;202(11):1028-1034.
6. Freis ED. Veterans Administration cooperative study on nadolol as monotherapy and in combination with a diuretic. Am Heart J. 1984;108(4 Pt 2):1087-1091.
7. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension, I: Results of short-term titration with emphasis on racial differences in response. Veterans Administration Cooperative Study Group on Antihypertensive agents. JAMA 1982;248(16):1996-2003.
8. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension, II: Results of long-term therapy. JAMA 1982;248(16):2004-2011.
9. Moser M. Current recommendations for the treatment of hypertension: Are they still valid? J Hypertens. 2002;Suppl.1:S3-S10.
10. Greenberg A. Diuretic complications. Am J Med Sci. 2000;319(1):10-24.
11. Freis ED. The efficacy and safety of diuretics in treating hypertension. Ann Intern Med. 1995 Feb 1;122(3):223-226.
12. Moser M. Lipid abnormalities and diuretics. Am. Fame. Physician. 1989 Oct;40(4):213-220.
13. Moser M. Diuretics should continue to be one of the preferred initial therapies in the management of hypertension: The argument for. J Clin Hypertens (Greenwich). 2005;2:111-116.
14. Midweek M, Weaseled P, Chant P, Holzgreve H. Serum lipoproteins during antihypertensive therapy with beta blockers and diuretics: A controlled long-term comparative trial. Clin Cardiol. 1987;10(2):94-98.
15. Lind L, Pollare T, Berne C, Lithell H. Long-term metabolic effects of antihypertensive drugs. Am Heart J. 1994;128(6 Pt 1):1177-1183.
16. Moser M. Current hypertension management: Separating fact from fiction. Cleve Clin J Med. 1993;60(1):27-37.
17. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: Principal results. Br Med J (Clin Res Ed). 1985;291(6488):97-104.
18. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: Principal results. BMJ. 1992 Feb;304(6824):405-412.
19. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: Main results from the HAPPHY trial. J Hypertens. 1987 Oct. 5;5:561-572.
20. Wikstrand J, Warnold I, Olsson G, et al. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 1988 Apr 1;259(13):1976-1982.
21. Weir MR, Moser M. Diuretics and beta-blockers: Is there a risk for dyslipidemia? Am Heart J. 2000 Jan;139(1 Pt 1):174-183.
22. Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during one year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003 Aug;21(8):1563-1574.
23. de Courten M, Ferrari P, Schneider M, et al. Serum lipoproteins during treatment with antihypertensive drugs. J Cardiovasc Pharmacol. 1993;22(Suppl 6):S98-S105.
24. Ames RP. Hyperlipidemia in hypertension: Causes and prevention. Am Heart J. 1991;122:1219-1224.
25. Horan MJ. Antihypertensive therapy and atherosclerosis. Am J Med Sci. 1991;301:402-405.
26. Helgeland A, Hjermann I, Holme I, Leren P. Serum triglycerides and serum uric acid in untreated and thiazide-treated patients with mild hypertension. The Oslo Study. Am J Med. 1978;64:34-38.
27. Johnson BF. The emerging problem of plasma lipid changes during antihypertensive therapy. J Cardiovasc Pharmacol. 1982; 4(Suppl. 2):S213-S221.
28. Medical Research Council Working Party on Mild to Moderate Hypertension. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet. 1981;2:539-543.
29. Yu T, Berger L, Sarkozi L, Kaung C. Effects of diuretics on urate and calcium excretion. Arch Intern Med. 1981;141:915-919.
30. Plante GE, Dessurault DL. Hypertension in elderly patients. A comparative study between indapamide and hydrochlorothiazide. Am J Med. 1988;84:98-103.
31. Johnson MW, Mitch WE. The risks of asymptomatic hyperuricaemia and the use of uricosuric diuretics. Drugs. 1981;21:220-225.
32. Langford HG, Blaufox MD, Borhani NO, et al .Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med. 1987;147:645-649.
33. Gurwitz JH, Kalish SC, Bohn RL, et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol. 1997;50:953-959.
34. Hollifield JW, Slaton PE. Thiazide diuretics, hypokalemia and cardiac arrhythmias. Acta Med Scand Suppl. 1981;647:67-73.
35. Holland OB, Nixon JV, Kuhnert L. Diuretic-induced ventricular ectopic activity. Am J Med. 1981;770:762-768.
36. Holland OB, Kuhnert L, Pollard J, et al. Ventricular ectopic activity with diuretic therapy. Am J Hypertens. 1988 Oct;1(4 Pt 1):380-385.
37. Papademetriou V, Burris JF, Notargiacomo A, Fletcher RD, Freis ED. Effect of diuretic therapy on ventricular arrhythmias in patients with or without left ventricular hypertrophy. Am Heart J. 1985;110:596-599.
38. Kostis JB, Lacy CR, Hall WD, et al The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. The SHEP Study Group. Am J Cardiol. 1994 Sep 1;74(5):464-467.
39. Madias JE, Madias NE, Gavras HP. Nonarrhythmogenicity of diuretic-induced hypokalemia. Its evidence in patients with uncomplicated hypertension. Arch Intern Med. 1984;144:2171-2176.
40. Lief PD, Belgin I, Mates J, Banl N. Diuretic-induced hypokalemia does not cause ventricular ectopy in uncomplicated essential hypertension. Kidney Int. 1984;25:205.
41. Papademetriou V, Notargiacomo A, Heine D, Fletcher RD, Freis ED. Effects of diuretic therapy and exercise-related arrhythmias in systemic hypertension. Am J Cardiol. 1989;64:1152-1156.
42. Papademetriou V, Fletcher R, Khatri IM, Freis ED. Diuretic-induced hypokalemia in uncomplicated systemic hypertension: Effect of plasma potassium correction on cardiac arrhythmias. Am J Cardiol. 1983;52:1017-1022.
43. Papademetriou V, Burris JF, Notargiacomo A, Fletcher RD, Freis ED. Thiazide therapy is not a cause of arrhythmias in patients with systemic hypertension. Arch Intern Med. 1988;145:1272-1278.
44. Siegel D, Hulley SB, Black DM, et al. Diuretics, serum and intracellular electrolyte levels and ventricular arrhythmias in hypertensive men. JAMA 1992;267:1683-1688.
45. Ma G, Srivastava NT, Anderson PG, et al. Elevated potassium intake inhibits neointimal proliferation in the swine coronary artery. Am J Hypertens. 2001;14:879-886.
46. Tobian L, Jahner TM, Johnson MA. High K diets markedly reduce atherosclerotic cholesterol ester deposition in aortas of rats with hypercholesterolemia and hypertension. Am J Hypertens. 1990 Feb;3(2):133-135.
47. Multiple Risk Factor Intervention Trial Research Group. Exercise electrocardiogram and coronary heart disease mortality in the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1985 Jan 1;55(1):16-24.
48. Lin H, Young D. Thrombosis/thrombolysis/vasodilator responses: Interaction between plasma potassium and epinephrine in coronary thrombosis in dogs. Circulation 1994;89:331-338.
49. McCabe RD, Bakarich MA, Srivastava K, Young DB. Potassium inhibits free radical formation. Hypertension. 1994;24:77-82.
50. Kimura M. Potassium chloride supplementation diminishes platelet reactivity in humans. Hypertension. 2004;44(6):969-973.
51. Siegel D, Hulley SB, Black DM, et al. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. JAMA. 1992;267:1083-9
52. Hoes AW, Grobbee DE, Lubsen J. Sudden cardiac death in patients with hypertension. An association with diuretics and beta-blockers? Drug Saf. 1997 Apr;16(4):233-241.
53. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 1996 Apr;27(5):1214-1218.
54. Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 1993 Mar 8;153(5):578-581.
55. Elliott WJ. ALLHAT: The largest and most important clinical trial in hypertension ever done in the USA. Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial. Am J Hypertens. 1996;9(4 Pt 1):409-411.
56. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981-2997.
57. Wing LM, Reid CM, Ryan P, et al. Second Australian National Blood Pressure Study Group A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348(7):583-592.
58. Moser M. Current recommendations for the treatment of hypertension: Are they still valid? J Hypertens Suppl. 2002;1:S3-S10.
59. Rosei EA, Dal Palu C, Leonetti G, et al. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. VHAS Investigators. J Hypertens. 1997;11:1337-1344.
60. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension - 2 study. Lancet 1999;354(9192):1751-1756.
61. Brown MJ, Palmer CR, Castaigne C, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356(9227):366- 372
62. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356(9227):359-365.
63. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003;289(16):2073-2082.
64. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomized trial. Lancet. 1999;353:611-616.
65. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-1041.
66. Dahlof B, Sever PS, Poulter NR, et al. ASCOT investigators prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906.
67. Weber MA. Creating a combination antihypertensive regimen: What does the research show? J Clin Hypertens (Greenwich). 2003;5(4 Suppl 3):12-20.
68. Jamerson KA. The first hypertension trial comparing the effects of two fixed-dose combination therapy regimens on cardiovascular events: Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH). J Clin Hypertens (Greenwich). 2003;5(4 Suppl. 3):29-35.
69. Jamerson KA, Bakris GL, Wun CC, et al. Rationale and design of the Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: The first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens. 2004;17(9):793-801.
70. Weder AB. The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A comparison of first-line combination therapies. Expert Opin Pharmacother. 2005;2:275-281.
71. Psaty BM, Lumley T, Furberg, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis. JAMA 2003;289(19):2534-2544.
72. Verdecchia P, Angeli F, Reboldi G, Gattobigio R. Is the development of diabetes with antihypertensive therapy a problem: Pro. J Clin Hypertens (Greenwich). 2006 Feb;8(2):120-126.
73. Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes Am J Cardiol. 2005;95(1):29-35.
74. Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive three different classes of antihypertensive treatment: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006;166(20):2191-2201.
75. Dahlof B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.
76. Opie L, Schall R Old antihypertensives and new diabetes. J Hypertens. 2004;8:1453-1458.
77. Messerli FH, Grossman E, Leonetti G. Antihypertensive therapy and new onset diabetes. J Hypertens. 2004;10:1845-1847.
78. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000;342(13):905-912.
79. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: A quantitative review. Hypertension 2006;48(2):219-224.
80. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the reninangiotensin system reduces the incidence of new-onset diabetes. J Hypertens. 2005;3:463-473.
81. Cooper ME, Tikellis C, Thomas MC. Links preventing diabetes in patients with hypertension: One more reason to block the renin-angiotensin system. J Hypertens. 2006;Suppl.1:S57-S63.
82. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs. 2004;64(22):2537-2565.
83. Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. DREAM Trial Investigators. N Engl J Med. 2006;355(15):1551-1562.
84. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet 2007 Jan 20;369(9557):201-207.
85. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003;289:2560-2571.
86. European Society of Hypertension - European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003 Jun;21(6):1011-1053.
87. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke and coronary heart disease, part 2: Short-term reductions in blood pressure: Overview or randomized drug trials in their epidemiological context. Lancet 1990;335:827-838.
88. Neal B, MacMahon S, Chapman N, Blood Pressure Lowering Treatment Trialists' Collaboration. Blood Pressure Lowering Treatment Trialists' Collaboration. ACE inhibitors, calcium antagonists and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomized trials. Lancet 2000;356:1955-1964.